Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Input: Consider Input: Funkturm Stuttgart is a reinforced concrete transmitting tower, built in 1966 on the Raichberg of Stuttgart, Germany (Geographical coordinates: 484627''N 91323''E).

Output: What material was used for Funkturm Stuttgart?

Input: Consider Input: Our clothes are a powerful tool that can make us feel better about ourselves. One way in which this works is by wearing different color1s of clothes. Normally when we are sad, we will wear dark color1ed clothes. Oppositely, when we are happy, we often choose to wear brightly color1ed clothes. The reason for this is that our choice of color1 mirrors is how we are feeling. Those who don't believe in the idea are often heard saying, "if only this truly worked". Well in reply to those people, there has been a lot of research into what happens to someone's feelings when they are asked to wear just one color1 of clothes. It has been proven that if we wear particular color1s of clothes they can change our feelings. Suppose we are feeling sad, if we wear black we may begin to feel worse. However, if we wear green, red or yellow, we may begin to feel better. Each color1 is said to have its own healing power. So remember, if you are not feeling your best, you can always try out some different color1ed clothes. If one color1 has no effect on your feelings, maybe another will.

Output: What's the author's attitude toward "wearing particular color1s of clothes can change our feelings"?

Input: Consider Input: With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients. Our expanding knowledge of the molecular processes underlying these conditions has resulted in novel bone targets that are currently being explored in clinical trials. Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years. Potential agents targeting the osteoclast include cathepsin K, currently in phase 3 trials, and src inhibitors. Amongst anabolic agents, inhibitors of the Wnt-inhibitor sclerostin and dickkopf-1 are promising in clinical trials. Here, we will provide a comprehensive overview of the most promising agents currently explored for the treatment of bone diseases.
Output: To the ligand of which receptors does Denosumab (Prolia) bind?